EGFR and glioma: Amplification of wild-type or mutant EGFR is relatively common (43% of GBM cases), with the most frequent mutation being EGFRvIII. Mutation and/or overexpression of EGFR or PDGFR are very well known markers of glioma malignancy [19,20].